NCT06579469
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 1 year 9 months later.
See at-risk trials from St. Jude Children's Research Hospital
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 20 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Mar 2027 to Jan 2029 Show 5 more changesShow less
- Eligibility criteria expanded, about 11 words
- Study completion pushed from Mar 2029 to Dec 2031
- Study sites: 6 to 7
- Secondary endpoints: details revised at 7 of 7 entries
- Study description expanded, about 5 words
- Minor Study sites: 5 to 6v19
- Minor Study sites: 4 to 5v18
- Minor Study sites: 3 to 4v17
- Minor Study sites: 2 to 3v16
Show 14 earlier versionsHide 14 earlier versions
- Minor Start date changed from estimate of Jan 2026 to Jan 20, 2026v15
- Minor Study sites: 1 to 2v14
- Notable Start date: Nov 2025 to Jan 2026v13
- Minor Start date: Oct 2025 to Nov 2025v12
- Notable Start date: Aug 2025 to Oct 2025v11
- Minor Start date: Jul 2025 to Aug 2025v10
- Minor Start date: Jun 2025 to Jul 2025v9
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: May 2025 to Jun 2025
- Site details revised
- Notable Start date: Mar 2025 to May 2025v7
- Notable Eligibility criteria expanded, about 6 wordsv6
- Minor Primary completion date: Feb 2027 to Mar 2027
- Study completion date: Feb 2029 to Mar 2029
- Start date: Feb 2025 to Mar 2025
- Minor Start date: Jan 2025 to Feb 2025v4
- Notable Start date: Nov 2024 to Jan 2025v3
- Minor Start date: Oct 2024 to Nov 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Presence of bone marrow dysfunction (BMD)
Timeframe: Within 6 months post CAR T-cell therapy
Occurrence of clinically significant infections
Timeframe: Within 6 months post CAR T-cell therapy
Presence of persistent ICANS
Timeframe: Within 6 months post CAR T-cell therapy
Secondary (7)
Presence of bone marrow dysfunction (BMD)
Severity of BMD
Occurrence of clinically significant infections
Time to the earliest clinically significant infection
Severity of clinically significant infections
Show 2 moreShow less
Presence of persistent ICANS
Severity of persistent ICANS
Arms and interventions
B cell acute lymphoblastic leukemia (B cell acute lymphoblastic leukemia (B-ALL) ) cohort
B-ALL participants who have received initial CAR T cell therapy within the last 1-3 months.
Other hematologic malignancy
Other hematologic malignancy participants who have received initial CAR T cell therapy within the last 1-3 months.
Solid tumor (ST)
ST participants who have received initial CAR T cell therapy within the last 1-3 months.
Sites
7 sites in 1 country